Indivior (NASDAQ:INDV) Releases Quarterly Earnings Results, Beats Expectations By $0.31 EPS

Indivior (NASDAQ:INDV) posted its quarterly earnings data on Thursday. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31, FiscalAI reports. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. The company had revenue of $317.00 million during the quarter, compared to analysts’ expectations of $272.64 million.

Here are the key takeaways from Indivior’s conference call:

• Strong commercial momentum — Q1 total net revenue was $317M (+19% YoY) driven by SUBLOCADE net revenue of $232M (+32% YoY), 20% dispense unit growth, record ~31,800 new patient starts, and over 500,000 U.S. patients prescribed since launch.
• Raised full?year outlook and margin expansion — management increased 2026 guidance with expected SUBLOCADE revenue $950–990M and Adjusted EBITDA $620–660M (midpoint $640M), targeting a ~51% EBITDA margin driven by unit acceleration and favorable mix.
• Improved balance sheet and capital allocation optionality — completed a $500M convertible note refinancing (reducing interest to 0.625%), repurchased $125M of shares and has roughly $275M remaining on the buyback, while signaling pursuit of commercial?stage M&A opportunities.
• Pipeline reprioritization and setbacks — INDV?6001 will not advance to Phase III (rights amended with Alar; Indivior retains U.S. commercial rights) and INDV?2000 failed its Phase II primary endpoint, so both programs will be de?emphasized internally and positioned for external business development.

Indivior Trading Up 7.7%

NASDAQ INDV traded up $2.63 on Thursday, hitting $36.78. 6,854,730 shares of the company were exchanged, compared to its average volume of 2,329,644. The company has a market cap of $4.48 billion, a PE ratio of 22.43 and a beta of 0.88. Indivior has a 12 month low of $10.63 and a 12 month high of $39.33. The stock has a fifty day moving average of $31.79 and a 200-day moving average of $32.38.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on INDV shares. Weiss Ratings cut shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, March 17th. HC Wainwright increased their price objective on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. Finally, Northland Securities set a $50.00 price objective on shares of Indivior in a research report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Indivior presently has an average rating of “Buy” and a consensus target price of $39.33.

Insider Transactions at Indivior

In related news, Director Stuart A. Kingsley bought 940 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an average cost of $31.86 per share, with a total value of $29,948.40. Following the completion of the purchase, the director directly owned 5,582 shares in the company, valued at $177,842.52. The trade was a 20.25% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in Indivior during the fourth quarter worth $344,000. Invesco Ltd. boosted its stake in Indivior by 274.6% during the fourth quarter. Invesco Ltd. now owns 286,689 shares of the company’s stock worth $10,286,000 after acquiring an additional 210,150 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Indivior during the fourth quarter worth $274,000. EP Wealth Advisors LLC bought a new position in Indivior during the fourth quarter worth $481,000. Finally, Fuller & Thaler Asset Management Inc. boosted its stake in Indivior by 101.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock worth $228,611,000 after acquiring an additional 3,201,639 shares in the last quarter. 60.33% of the stock is owned by institutional investors.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.